Background: Ovarian cancer presents a major clinical challenge in the UK. Glycogen synthase kinase-3 (GSK-3) has been linked to cancer. This study tested the impact of
ShenLingLan (
SLDM) on ovarian cancer cell behaviour and its links to GSK-3.
Methods: Fresh ovarian tumours (
n = 52) were collected and processed. Histopathologcial and clinical information were collected and analysed against GSK-3 transcript levels using quantitative PCR (qPCR). Immortalised ovarian cancer cells’ protein alterations in response to
SLDM were identified using a Kinexus™ protein kinase array. The effects of
SLDM and a combination of
SLDM and TWS119 on ovarian cancer cells ability to attach and migrate were evaluated using electrical cell-substrate impedance sensing (ECIS).
Results: Transcript expression of GSK-3β was significantly increased in ovarian tumours which were poorly differentiated, patients with recurrence and in patients who had died from ovarian cancer. Treating SKOV-3 ovarian cells with
SLDM reduced GSK-3 expression and GSK-3α (Y279). Treatment with
SLDM reduced ovarian cancer cells ability to attach and migrate, which was further reduced in the presence of TWS119.
Conclusions: This study identified a potential mechanism by which
SLDM may exert anti-metastatic effects. Further work is needed to investigate the in vivo effects
SLDM has on ovarian tumours.
Full article